The arrival of Retatrutide ZPHC, at a strength of 120mg, is sparking considerable buzz within the medical community. This novel dual GIP and GLP-1 receptor medication appears to provide impressive improvements in body reduction compared to existing therapies. Early research trials have demonstrat